Pilot study on the influence of Sutent on tumor vascularization and necrosis in patients with renal cell carcinoma.

• Conditions: renal cell carcinoma renal cell cancer; 10038595

• Registration Number: NL-OMON30373
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 5

Inclusion Criteria

- patients with metastatic renal cell cancer for whom treatment with Sutent is planned
- measurable primary tumor or metastases (minimal diameter 2 cm) at other sites than the lungs
- Karnofsky score equal or larger than 70%
- age equal or higher than 18 year.
- written informed consent

Exclusion Criteria

- contra-indications for MRI
- contra-indications for treatment with Sutentâ

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Observational. Measurement of Kep, Ktrans, R2*, b-coefficent (perfusion,<br /><br>hypoxia, blood volume and necrosis)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>No</p><br>